Stock Events

Stock Events

Search...

MGC Pharmaceuticals

$0.24

57

-$0.03-11.21% Friday 16:55

Statistics

Day High

0.27

Day Low

0.27

52W High

6.9

52W Low

0.23

Volume

1,000

Avg. Volume

265

Mkt Cap

12.11M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

30JunConfirmed

Q3 2019

Q4 2019

Q1 2020

Q2 2020

Q3 2020

Q4 2020

Q1 2021

-0

-0

-0

0

Expected EPS

0

Actual EPS

-0.0016

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MGCLF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is a global pharmaceutical company that competes in various therapeutic areas, including those Argent Biopharma is involved in.

Merck operates in similar therapeutic areas as Argent Biopharma, making them direct competitors in the pharmaceutical industry.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division Janssen, competes with Argent Biopharma in developing treatments for various diseases.

AbbVie competes in the biopharmaceutical field, focusing on areas like immunology and oncology, which may overlap with Argent Biopharma's interests.

Amgen is a biotechnology company that develops innovative therapeutics, potentially in competition with Argent Biopharma's product pipeline.

Bristol-Myers Squibb

Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines that could compete with Argent Biopharma's offerings.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that focuses on areas such as infectious diseases, where Argent Biopharma may also be active.

Novartis is a global healthcare company that operates in various therapeutic areas, potentially competing with Argent Biopharma.

Roche Holding AG, through its pharmaceuticals and diagnostics divisions, competes in the development of innovative healthcare solutions.

Sanofi is a global biopharmaceutical company focusing on human health, directly competing with Argent Biopharma in several therapeutic areas.

About

Precious Metals

Pharmaceuticals: Other

Health Technology

Process Industries

Agricultural Commodities/Milling

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.

Show more...

CEO

Roby Zomer

Country

AU

ISIN

AU000000MXC6

WKN

000A2ACB6

Listings